This is a news story, published by MSN, that relates primarily to Kisunla news.
For more Kisunla news, you can click here:
more Kisunla newsFor more disease research news, you can click here:
more disease research newsFor more news from MSN, you can click here:
more news from MSNOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like disease research news, you might also like this article about
Alzheimer. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest early symptomatic Alzheimer news, DEMENTIA news, disease research news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
major AlzheimerFox News
•
74% Informative
An estimated 6.9 million Americans aged 65 and older currently live with Alzheimer's disease.
2024 saw a new drug enter the dementia landscape, as the U.S. Food and Drug Administration ( FDA ) approved Kisunla (donanemab) in July .
Air pollution has been linked to an increased risk of dementia, according to 2024 research.
VR Score
80
Informative language
83
Neutral language
54
Article tone
formal
Language
English
Language complexity
64
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links